Evidence map›Paper›PMID 38433247›Full record

ArticleExperimental & molecular medicine2024

Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability.

Ken Takasawa, Ken Asada, Syuzo Kaneko, Kouya Shiraishi, Hidenori Machino, Satoshi Takahashi, Norio Shinkai, Nobuji Kouno, Kazuma Kobayashi, Masaaki Komatsu and 11 more

Open access · goldAbstract read
In one paragraph

Article in Experimental & molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Methods in DNA methylation array dataset analysis: A review.Computational and structural biotechnology journal · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Ken Takasawa *Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. ktakazaw@ncc.go.jp.
Ken Asada *Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Syuzo Kaneko *Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Hidenori MachinoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0001-6843-7696
Satoshi TakahashiDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Norio ShinkaiDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Nobuji KounoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Kazuma KobayashiDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Masaaki KomatsuDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Takaaki MizunoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Yu OkuboDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Masami MukaiDivision of Medical Informatics, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Tatsuya YoshidaDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yukihiro YoshidaDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Hidehito HorinouchiDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Shun-Ichi WatanabeDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0003-1788-559X
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Ryuji HamamotoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. rhamamot@ncc.go.jp.ORCID http://orcid.org/0000-0002-2632-1334
RIKEN Center for Advanced Intelligence Project · JPTokyo National Hospital · JPNational Cancer Centre Japan · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP22ck0106643MEXT | Japan Science and Technology Agency (JST) JPMJCR18Y4MEXT | Japan Society for the Promotion of Science (JSPS) JP18H04908MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR1689
6 · The paper itself

Abstract

DNA methylation is an epigenetic modification that results in dynamic changes during ontogenesis and cell differentiation. DNA methylation patterns regulate gene expression and have been widely researched. While tools for DNA methylation analysis have been developed, most of them have focused on intergroup comparative analysis within a dataset; therefore, it is difficult to conduct cross-dataset studies, such as rare disease studies or cross-institutional studies. This study describes a novel method for DNA methylation analysis, namely, methPLIER, which enables interdataset comparative analyses. methPLIER combines Pathway Level Information Extractor (PLIER), which is a non-negative matrix factorization (NMF) method, with regularization by a knowledge matrix and transfer learning. methPLIER can be used to perform intersample and interdataset comparative analysis based on latent feature matrices, which are obtained via matrix factorization of large-scale data, and factor-loading matrices, which are obtained through matrix factorization of the data to be analyzed. We used methPLIER to analyze a lung cancer dataset and confirmed that the data decomposition reflected sample characteristics for recurrence-free survival. Moreover, methPLIER can analyze data obtained via different preprocessing methods, thereby reducing distributional bias among datasets due to preprocessing. Furthermore, methPLIER can be employed for comparative analyses of methylation data obtained from different platforms, thereby reducing bias in data distribution due to platform differences. methPLIER is expected to facilitate cross-sectional DNA methylation data analysis and enhance DNA methylation data resources.

Indexed as

DNA MethylationNeoplasmsAlgorithmsCross-Sectional StudiesEpigenesis, GeneticHumans

Identifiers

PMID38433247
PMCPMC10985003
OpenAlexW4392342199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.